Who Paid My Doc
A Randomized, Multicenter, Double-Blind, Phase 3 Study to Investigate
Research payments
$512,747
Through program year 2025, $512,747 in research payments was reported against A Randomized, Multicenter, Double-Blind, Phase 3 Study to Investigate, across 150 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $468,827 | 128 |
| 2024 | Research | $43,920 | 22 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Firas Badin Lexington, KY Named on 19 payments
- Jonathan Riess Sacramento, CA Named on 14 payments
- Timothy Dorius Council Bluffs, IA Named on 13 payments
- Christopher Vaughn Fredericksburg, VA Named on 13 payments
- Ray Page Fort Worth, TX Named on 12 payments
- Colleen Darnell Edgewood, KY Named on 12 payments
- Joseph Ye Olympia, WA Named on 12 payments
- Jennifer Carney Honolulu, HI Named on 11 payments
- Wade Iams Nashville, TN Named on 11 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.